# Effectiveness of Indoor Air Purifiers on Heart Failure Outcomes (The PURI-HF Trial)

> **NIH NIH R01** · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · 2022 · $339,000

## Abstract

Project Abstract: Effectiveness of Indoor Air Purifiers on Heart Failure Outcomes (PURI-HF Trial)
Indoor air pollution is one of the leading risk factors for global mortality, with over 90% of pollution-related
deaths occurring in low- and middle- income countries (LMICs). Fine mode particulate matter with an
aerodynamic diameter smaller than 2.5 micrometers (PM2.5) is a major contributor to global morbidity and
mortality, particularly due to cardiovascular disease (CVD). There is a strong link between both acute and
chronic PM2.5 air pollution exposure and heart failure (HF) incidence, hospitalizations, and mortality. Most
recommendations to reduce air pollution-mediated CVD have focused on improved cooking techniques
and ventilation, but with mixed results. New strategies to improve air quality and cardiovascular health are
needed. For the past few decades, high-efficiency particulate air (HEPA) purifiers have been studied in
LMICs to decrease PM2.5 pollution and improve health outcomes. However, there remain substantial gaps
in understanding the long-term effects of air purifiers on functional and clinical HF outcomes. We are an
established group of investigators with a successful track record of innovative and impactful studies at the
intersection of air pollution and CVD. We will leverage our experience to study the impact of an innovative
approach to reduce the adverse impact of air pollution and improve HF outcomes in India. The PURI-HF
Trial aims to demonstrate the efficacy, feasibility and effectiveness of portable air filters in improving
indoor PM2.5 levels and improving functional capacity of HF patients with reduced ejection fraction (HFrEF)
in India. Our proposed partnership between NYU Grossman School of Medicine and All India Institute of
Medical Sciences will emphasize capacity building and cross-institutional training opportunities throughout
the duration of the project. Aim 1 will be a randomized controlled trial to evaluate the effectiveness of
indoor air purifiers on HF functional capacity (6-minute walk test) among patients with HReEF in Delhi,
Ludhiana, and Thiruvananthapuram. We will also conduct a moderation analysis to evaluate whether level
of ambient air pollution, as well as spatial/environmental factors, moderate the impact of air purifiers on
HF outcomes. Aim 2 will involve a causal mediation analysis to determine if the reduction in PM2.5 is
associated with the relationship between air purifiers and HF outcomes. We will also assess whether
seasonality correlates with the reduction in indoor PM2.5 concentrations in participant households, and
we will determine the impact of air purifier use on the composition of PM2.5 air pollution in the three study
sites. Aim 3 will be comprised of a cost-effectiveness analysis and process evaluation of the intervention.
The research will be conducted by a transdisciplinary research team with diverse and complementary
expertise led by two experienced Principal Investigators. We in...

## Key facts

- **NIH application ID:** 10494126
- **Project number:** 5R01ES033222-02
- **Recipient organization:** NEW YORK UNIVERSITY SCHOOL OF MEDICINE
- **Principal Investigator:** NITISH NAIK
- **Activity code:** R01 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2022
- **Award amount:** $339,000
- **Award type:** 5
- **Project period:** 2021-09-25 → 2026-06-30

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10494126

## Citation

> US National Institutes of Health, RePORTER application 10494126, Effectiveness of Indoor Air Purifiers on Heart Failure Outcomes (The PURI-HF Trial) (5R01ES033222-02). Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/grant/nih/10494126. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*